“The Applicant identified the hamster and monkey as pharmacologically relevant species for toxicology testing with evolocumab; both species express PCSK9, to which evolocumab binds with high affinity.”
✓ VerifiedFDA pharmacology/toxicology review, p. 11Source ↗
Why that species
High-affinity binding to human, cynomolgus monkey and hamster PCSK9 (KD 16, 8 and 14 pM)
“Evolocumab binds to human, cynomolgus monkey and hamster PCSK9 with high affinity (KD = 16, 8 and 14 pM, respectively; see Table 2).”
✓ VerifiedFDA pharmacology/toxicology review, p. 29Source ↗
Surrogate molecule
No surrogate; the clinical antibody was tested in hamster and cynomolgus monkey
“Evolocumab is pharmacological active in human, Cynomolgous monkey and hamster. The latter two were used in toxicology studies, where also the pharmacodynamics parameters were measured.”